



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

MAH compliance with PRAC signal recommendations for PI update of CAPs

PRAC recommendations May15-Apr16

10th Industry stakeholder platform – operation of EU pharmacovigilance

Presented by Aniello Santoro on 3 February 2017
Signal and Incident Management - Pharmacovigilance department

An agency of the European Union





Background

1st Compliance check of signal PRAC recommendations for PI update (Sep12-Apr15)

- All PRAC signal recommendations for PI update involving CAPs had been implemented
- Majority of variations submitted in compliance with required timeline
- Sequential submissions for generics led to delay in updates to their PI (up to **10 m**)

Sep 15: Concurrent submissions for generics


- Objective: to save time to implement PRAC recommendations in PI of generics
- Awareness:
 - published PRAC recommendations
 - Q&A on Signal Management
 - "What's new in Pharmacovigilance - QPPV update" sent to all EU QPPVs
 - EGA-EMA Annual bilateral meeting (27Jan16)

Current compliance check

- **Objective:** to check level of MAH compliance with PRAC recommendations for PI update in the context of signal assessment
- **Timeframe:** PRAC recommendations between May 2015 - Apr 2016
- **Scope:** Only PRAC recommendations for substances contained in CAPs
- **Sources:** SIAMED (records on variations for CAPs) + EPITT (records on signals) + ad-hoc liaison with relevant functions for clarifications




Records in EPITT





Submission of variations



Findings

- Generic MAHs submitted variations sooner (concurrent submission):
 - within the same timeline (1-3m) as Innovator (previously up to 10m after PRAC recommendation)
 - during first 4 m (subsequent submissions) 1 generic MAH submitted in compliance but ~ 1 m later than the deadline for Innovator $\implies$ *This extra-time is now saved with concurrent submissions*
- Delayed submissions:
 - mainly generics (apart from 1 Innovator, borderline). 6 variations (4 signals), 3 of which from same MAH; the other 3 for 3 different MAHs
 - Reason: not aware of implementation of concurrent submission and awaiting for notification from EMA

Conclusions

- variations for all PRAC recommendations for PI update for CAPs have been submitted
 - **91% (= 60 variations)** submitted **within** the required timeline (e.g. 30, 60 or 90 days)
 - **9% (= 6 variations)** submitted **late**. Of those:
 - 1/3 (= 2 variations, 1 signal) borderline for compliance (only 4 d late)
 - 2/3 (= 4 variations, 3 signals) later than 2 m after recommended timeline, majority from the same MAH
- quicker implementation of PI update for generics



- next compliance check in 2017 (PRAC recommendations from May 2016 to April 2017)

- CAP: Centrally Authorised Product
- EMA: European Medicines Agency
- EPITT: European Pharmacovigilance Issues Tracking Tool
- EU: European Union
- MAH: Marketing Authorisation Holder
- PI: Product Information
- PRAC: Pharmacovigilance Risk Assessment Committee
- QPPV: Qualified Person responsible for Pharmacovigilance



Thank you for your attention

Further information

European Medicines Agency

30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom

Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555

Send a question via our website www.ema.europa.eu/contact

Follow us on  **@EMA_News**

